- Home
- ANVS vs YHNA Comparison
ANVS vs YHNA Comparison
Compare ANVS & YHNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- YHNA
- Stock Information
- Founded
- ANVS 2008
- YHNA 2023
- Country
- ANVS United States
- YHNA Hong Kong
- Employees
- ANVS N/A
- YHNA N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- YHNA
- Sector
- ANVS Health Care
- YHNA
- Exchange
- ANVS Nasdaq
- YHNA Nasdaq
- Market Cap
- ANVS 92.6M
- YHNA 79.9M
- IPO Year
- ANVS 2020
- YHNA 2024
- Fundamental
- Price
- ANVS $5.01
- YHNA $10.07
- Analyst Decision
- ANVS Strong Buy
- YHNA
- Analyst Count
- ANVS 6
- YHNA 0
- Target Price
- ANVS $29.67
- YHNA N/A
- AVG Volume (30 Days)
- ANVS 488.6K
- YHNA 21.1K
- Earning Date
- ANVS 11-08-2024
- YHNA 01-01-0001
- Dividend Yield
- ANVS N/A
- YHNA N/A
- EPS Growth
- ANVS N/A
- YHNA N/A
- EPS
- ANVS N/A
- YHNA N/A
- Revenue
- ANVS N/A
- YHNA N/A
- Revenue This Year
- ANVS N/A
- YHNA N/A
- Revenue Next Year
- ANVS N/A
- YHNA N/A
- P/E Ratio
- ANVS N/A
- YHNA N/A
- Revenue Growth
- ANVS N/A
- YHNA N/A
- 52 Week Low
- ANVS $4.21
- YHNA $10.00
- 52 Week High
- ANVS $20.00
- YHNA $11.28
- Technical
- Relative Strength Index (RSI)
- ANVS 44.02
- YHNA N/A
- Support Level
- ANVS $4.61
- YHNA N/A
- Resistance Level
- ANVS $4.95
- YHNA N/A
- Average True Range (ATR)
- ANVS 0.38
- YHNA 0.00
- MACD
- ANVS 0.07
- YHNA 0.00
- Stochastic Oscillator
- ANVS 40.40
- YHNA 0.00
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About YHNA YHN Acquisition I Limited Ordinary Shares
YHN Acquisition I Ltd is a newly organized blank check company for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities.